Emetogenic Chemotherapy.
Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens
... of emetogenic risks for each anticancer drug and regimen [4–7], resulting in categories of high emetogenic chemotherapy (HEC), moderate emetogenic chemother- apy (MEC), low emetogenic, ...
10
Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials
... We performed a pooled analysis to evaluate the efficacy and adverse events (AEs) of olanzapine combined with dexamethasone plus 5- hydroxytryptamine type 3 receptor antagonist (5- HT3 RA) compared with 5- HT3 RA plus ...
8
Cost utility analysis of palonosetron in the antiemetic regimen for cisplatin containing highly emetogenic chemotherapy in Japan
... TRIPLE study, the primary endpoint was complete response (CR; no vomiting/nausea and no rescue medica- tion) within 120 h after cisplatin-containing HEC. Eligible patients were randomly assigned to double-blind anti- ...
10
A Study Comparing the Efficacy of Ondansetron, Palenosetron and Aprepitant in the Prevention of Chemotherapy induced Nausea and Vomiting in Breast Cancer patients receiving Moderately Emetogenic Chemotherapy.
... evaluating the role of newer anti emetics in the prevention of CINV in patients receiving Moderately emetogenic chemotherapy (MEC).The scenario of anti emetic prophylaxis is also less clear regarding the ...
82
<p>Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study</p>
... moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy ...common chemotherapy regi- men and is classified as a ...
9
Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)
... 19. Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E. Italian trials in medical oncology group: Palonosetron in combination ...
9
<p>Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy</p>
... The two initial bioequivalence studies evaluated HTX-019 infused for 30 mins; however, an acute shortage of IV fl uids and bags, along with the desire to reduce administration times, has prompted the administration of ...
8
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
... Methods: In C2005-01, 45 patients received APF530 250, 500, or 750 mg SC (granisetron 5, 10, or 15 mg, respectively). In C2007-01, 35 patients were randomized to APF530 250 or 500 mg SC. Injections were given 30 to 60 ...
10
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
... following chemotherapy, the number of nausea, retching and/ or vomiting episodes, and instances of rescue medication use; these data were used to evaluate the above-mentioned efficacy ...
9
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
... Chemotherapy-induced nausea and vomiting is a signifi- cant side effect of cancer therapy for many years[1]. CR for acute period and delayed period in the patients receiving highly and moderately emetogenic ...
7
Randomized Double Blind Trial to Compare the Efficacy of Granisetron And Ondansetron in Controlling Emesis in Children with Acute Lymphoblastic Leukemia
... their findings. A different randomized study on ondansetron in patients treated with high emetogenic chemotherapy had supported the superiority of higher doses of ondansetron over lower dose 20 . But our ...
7
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
... highly emetogenic chemotherapy (HEC), the percentage with no nausea (response of 0 on the VAS) significantly improved compared with control in the acute phase (74% vs 45%; P= ...
9
Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
... of chemotherapy and the proportion with minimal or no impact on daily life according to the FILE questionnaire were significantly higher in favor of the aprepitant-containing regi- men, 51% vs 42% (P = ...
10
Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
... highly emetogenic chemotherapy, adding aprepitant to standard antiemetic therapy with dexamethasone and a serotonin antagonist significantly improved control of ...
16
Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting
... The growing understanding of the role of substance P in emesis led to the development of NK-1 receptor antagonists for the treatment of delayed CINV. The first oral NK-1 recep- tor antagonist, aprepitant, was approved in ...
10
Prevention of cisplatin‑based chemotherapy‑induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison
... This meta‑analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‑Analyses (PRISMA) guidelines [47, 48]. A comprehensive literature search of the PubMed, MEDLINE, EMBASE, ...
13
A PROSPECTIVE CLINICAL STUDY ON THE BENEFIT OF ADDING CHEMOTHERAPY TO BRACHYTHERAPY IN PATIENTS WITH INCOMPLETE RESPONSE TO EXTERNAL BEAM IRRADIATION WITH CONCURRENT CHEMOTHERAPY IN LOCALLY ADVANCED CASES OF CARCINOMA CERVIX
... Since Indian radiation oncologists are faced with bulkier cervical tumours than their stage matched foreign counterparts , bigger residuals post concurrent external beam radiotherapy are a common finding and ...
11
Understanding chemotherapy
... Because skin and nail cells grow quickly, some chemotherapy drugs can affect them. Your skin may become dry, flaky, red and itchy. It can also be sensitive to sun and sea or chlorine in swimming pools. With ...
47
Original Article Effects of postoperative chemotherapy on cardiopulmonary complications in patients with esophageal cancer
... are in the radiation field. It has been well-estab- lished that pneumonia is a serious medical complication and a serious surgical complica- tion after esophagectomy procedures [16]. Pneumonia has a negative impact on ...
8
Click here to download PDF version of the article !
... and nutritional support. His hospital stay was prolonged to 45 days. The second patient developed intestinal obstruction during postoperative day 7-9 for which she underwent re-laparotomy and found to have adhesive ...
5